Fig. 2
From: Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth
M1 vaccine induces neoantigen specific immune responses against MC38 cells. Mice were vaccinated with three biweekly injections of M1 vaccine, which encodes 10 neoantigens from the MC38 colon cancer and a reference CD8 epitope from CEA, immune responses were evaluated in the periphery blood and in the splenocytes by FC. (a) Scheme of M1 vaccine and experimental set up. Numbers in M1 vaccine correspond to neoantigens listed in Table 1. (b) One week after last immunization T cell immune responses were analyzed in the peripheral blood for the expression of IFN-γ and TNF-α by FC PBMC were restimulated overnight with a pool of 10 neoantigen peptides from 1 to 10, dots represent value of single mice the gating strategy is shown in Additional file 2: Figure S1. (c) On day 42 immune responses against single peptides were analyzed by FC in restimulated splenocytes of four mice for the expression of IFN-γ, dots represent value of single mice